SAN DIEGO--( BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced poster presentations of clinical experience data from two studies of NUPLAZID ®(pimavanserin) in Parkinson’s disease psychosis (PD Psychosis) at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles.
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться